Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 3/20 | 0.50 |
| ▸ | CA1 | P00915 | 3/20 | 0.50 |
| ▸ | CA2 | P00918 | 3/20 | 0.50 |
| ▸ | CA7 | P43166 | 3/20 | 0.50 |
| ▸ | CA9 | Q16790 | 3/20 | 0.50 |
| ▸ | CA14 | Q9ULX7 | 3/20 | 0.50 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.50 |
| ▸ | GAA | P10253 | 2/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | CA4 | P22748 | 1/20 | 0.50 |
| ▸ | CA6 | P23280 | 1/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.47 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.47 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.46 |
| ▸ | HSD17B14 | Q9BPX1 | 3/20 | 0.45 |
| ▸ | DBH | P09172 | 1/20 | 0.44 |
| ▸ | RECQL | P46063 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18993050 | 0.85 | HDAC1 (0.62) | CA12CA1CA2CA7CA9 | |
| SCHEMBL19003399 | 0.82 | CA12 (0.56) | CA12CA1CA2CA7CA9 | |
| SCHEMBL10964767 | 0.81 | GAA (0.55) | KDM4EGAAMAPTL3MBTL1RECQL | |
| SCHEMBL1918258 | 0.81 | HDAC1 (0.61) | CA12CA1CA2CA7CA9 | |
| SCHEMBL1758192 | 0.79 | CA12 (0.68) | CA12CA1CA2CA7CA9 | |
| SCHEMBL30152409 | 0.78 | SIRT1 (0.61) | GAAPOLBMAPTSIRT1HDAC1 | |
| SCHEMBL19003425 | 0.77 | SIRT1 (0.51) | CA12CA1CA2CA7CA9 | |
| SCHEMBL19003400 | 0.77 | SNCA (0.53) | CA12CA1CA2CA7CA9 | |
| SCHEMBL10589365 | 0.75 | FASN (0.62) | CA12CA1CA2CA7CA9 | |
| SCHEMBL21935558 | 0.75 | CA12 (0.58) | CA12CA1CA2CA7CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11639325-B2 | Compositions of polyhydroxylated benzophenones and methods of treatment of neurodegenerative disorders | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2023-05-02 | — | — | US | disclosed |
| US-11639325-B2 | Compositions of polyhydroxylated benzophenones and methods of treatment of neurodegenerative disorders | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2023-05-02 | — | — | US | disclosed |
| US-11180438-B2 | Compositions of polyhydroxylated benzophenones and methods of treatment of neurodegenerative disorders | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2021-11-23 | — | — | US | disclosed |
| US-20210171429-A1 | COMPOSITIONS OF POLYHYDROXYLATED BENZOPHENONES AND METHODS OF TREATMENT OF NEURODEGENERATIVE DISORDERS | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2021-06-10 | — | — | US | disclosed |
| US-20200087236-A9 | COMPOSITIONS OF POLYHYDROXYLATED BENZOPHENONES AND METHODS OF TREATMENT OF NEURODEGENERATIVE DISORDERS | THE GENERAL HOSPITAL CORPORATION D/B/A MASSACHUSETTS GENERAL HOSPITAL (US) | 2020-03-19 | — | — | US | disclosed |
| EP-3390347-A1 | COMPOSITIONS OF POLYHYDROXYLATED BENZOPHENONES AND METHODS OF TREATMENT OF NEURODEGENERATIVE DISORDERS | Massachusetts Institute of Technology (US) | 2018-10-24 | — | — | EP | disclosed |
| WO-2017106861-A1 | COMPOSITIONS OF POLYHYDROXYLATED BENZOPHENONES AND METHODS OF TREATMENT OF NEURODEGENERATIVE DISORDERS | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2017-06-22 | — | — | WO | disclosed |
| WO-2017106861-A1 | COMPOSITIONS OF POLYHYDROXYLATED BENZOPHENONES AND METHODS OF TREATMENT OF NEURODEGENERATIVE DISORDERS | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2017-06-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11639325-B2 | Compositions of polyhydroxylated benzophenones and methods of treatment of neurodegenerative disorders | HDAC1, HDAC10, HDAC6 | CA12 3937/4885CA1 1764/4885CA2 4324/4885 |
| US-11180438-B2 | Compositions of polyhydroxylated benzophenones and methods of treatment of neurodegenerative disorders | HDAC1, HDAC10, HDAC6 | CA12 3937/4885CA1 1764/4885CA2 4324/4885 |
| US-20200087236-A9 | COMPOSITIONS OF POLYHYDROXYLATED BENZOPHENONES AND METHODS OF TREATMENT OF NEURODEGENERATIVE DISORDERS | HDAC1, HDAC10, HDAC6 | CA12 3937/4885CA1 1764/4885CA2 4324/4885 |
| US-20210171429-A1 | COMPOSITIONS OF POLYHYDROXYLATED BENZOPHENONES AND METHODS OF TREATMENT OF NEURODEGENERATIVE DISORDERS | HDAC1, HDAC10, HDAC6 | CA12 3937/4885CA1 1764/4885CA2 4324/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.